{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=100+mg%2Fm2+dose&page=2", "query": { "intervention": "100 mg/m2 dose", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 858, "total_pages": 86, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=100+mg%2Fm2+dose&page=3&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=100+mg%2Fm2+dose&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-01T02:15:36.758Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00267865", "title": "Chemotherapy and HAART to Treat AIDS-related Primary Brain Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "AIDS-Related-Primary Central Nervous System Lymphoma" ], "interventions": [ { "name": "Methotrexate", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 12, "start_date": "2006-09-14", "completion_date": "2019-09-19", "has_results": true, "last_update_posted_date": "2020-06-01", "last_synced_at": "2026-10-01T02:15:36.758Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00267865" }, { "nct_id": "NCT00856830", "title": "Bendamustine With Irinotecan Followed by Etoposide/Carboplatin for Patients With Extensive Stage Small Cell Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Small Cell Lung Cancer", "Extensive Stage Lung Cancer", "Chemonaive" ], "interventions": [ { "name": "Novel Drug Combination", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Alabama at Birmingham", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "79 Years", "sex": "ALL", "summary": "18 Years to 79 Years" }, "enrollment_count": 30, "start_date": "2009-04", "completion_date": "2016-05", "has_results": true, "last_update_posted_date": "2017-07-17", "last_synced_at": "2026-10-01T02:15:36.758Z", "location_count": 2, "location_summary": "Birmingham, Alabama • Marietta, Georgia", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Marietta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT00856830" }, { "nct_id": "NCT00064337", "title": "S0115, High-Dose Melphalan and Autologous Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma or Primary Systemic Amyloidosis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Multiple Myeloma", "Plasma Cell Myeloma" ], "interventions": [ { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "dexamethasone", "type": "DRUG" }, { "name": "melphalan", "type": "DRUG" }, { "name": "thalidomide", "type": "DRUG" }, { "name": "peripheral blood stem cell transplantation", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE" ], "sponsor": "SWOG Cancer Research Network", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 104, "start_date": "2004-01", "completion_date": "2015-11", "has_results": true, "last_update_posted_date": "2018-08-09", "last_synced_at": "2026-10-01T02:15:36.758Z", "location_count": 35, "location_summary": "Little Rock, Arkansas • Sacramento, California • Boise, Idaho + 19 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Sacramento", "state": "California" }, { "city": "Boise", "state": "Idaho" }, { "city": "Kansas City", "state": "Kansas" }, { "city": "Salina", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00064337" }, { "nct_id": "NCT00516282", "title": "VNP40101M and Temozolomide in Treating Patients With Progressive or Relapsed Malignant Glioma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Brain and Central Nervous System Tumors" ], "interventions": [ { "name": "CLORETAZINE", "type": "DRUG" }, { "name": "temozolomide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Northwestern University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 14, "start_date": "2007-08", "completion_date": "2009-10", "has_results": false, "last_update_posted_date": "2011-08-26", "last_synced_at": "2026-10-01T02:15:36.758Z", "location_count": 2, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00516282" }, { "nct_id": "NCT04209790", "title": "Neoadjuvant Chemoradiation for Resectable Glioblastoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Glioblastoma", "Surgery", "High Grade Glioma" ], "interventions": [ { "name": "Neoadjuvant chemoradiation", "type": "RADIATION" }, { "name": "Drug Therapy with Temozolomide (benzolamide) (Standard of Care)", "type": "DRUG" }, { "name": "Surgery post Radiation and Temozolomide (benzolamide)", "type": "PROCEDURE" } ], "intervention_types": [ "RADIATION", "DRUG", "PROCEDURE" ], "sponsor": "Geisinger Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "89 Years", "sex": "ALL", "summary": "18 Years to 89 Years" }, "enrollment_count": 2, "start_date": "2020-04-01", "completion_date": "2022-09-14", "has_results": true, "last_update_posted_date": "2025-11-10", "last_synced_at": "2026-10-01T02:15:36.758Z", "location_count": 2, "location_summary": "Danville, Pennsylvania • Wilkes-Barre, Pennsylvania", "locations": [ { "city": "Danville", "state": "Pennsylvania" }, { "city": "Wilkes-Barre", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT04209790" }, { "nct_id": "NCT00670410", "title": "Autologous Transplant Followed by Allogeneic Transplant for High Risk Neuroblastoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Neuroblastoma" ], "interventions": [ { "name": "Related donor transplant", "type": "PROCEDURE" }, { "name": "Cord blood transplant", "type": "PROCEDURE" }, { "name": "Busulfan", "type": "DRUG" }, { "name": "Thymoglobulin", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "Columbia University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "30 Years", "sex": "ALL", "summary": "Up to 30 Years" }, "enrollment_count": 15, "start_date": "2003-11", "completion_date": "2010-12", "has_results": false, "last_update_posted_date": "2016-06-24", "last_synced_at": "2026-10-01T02:15:36.758Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00670410" }, { "nct_id": "NCT02422979", "title": "Study of RM-1929 and Photoimmunotherapy in Patients With Recurrent Head and Neck Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Recurrent Head and Neck Cancer" ], "interventions": [ { "name": "PIT: 50 J/cm^2 for superficial lesions or 100 J/cm for interstitial lesions and Drug RM-1929: 160 mg/m^2", "type": "COMBINATION_PRODUCT" }, { "name": "PIT: 50 J/cm^2 for superficial lesions or 100 J/cm for interstitial lesions and Drug RM-1929: 320 mg/m^2", "type": "COMBINATION_PRODUCT" }, { "name": "PIT: 50 J/cm^2 for superficial lesions or 100 J/cm for interstitial lesions and Drug RM-1929: 640 mg/m^2", "type": "COMBINATION_PRODUCT" }, { "name": "PIT: 75 J/cm^2 for superficial lesions or 150 J/cm for interstitial lesions and Drug RM-1929: 640mg/m^2", "type": "COMBINATION_PRODUCT" }, { "name": "PIT: 100 J/cm^2 for superficial lesions or 200 J/cm for interstitial lesions and Drug RM-1929: 640mg/m^2", "type": "COMBINATION_PRODUCT" }, { "name": "PIT: 50 J/cm^2 for superficial lesions or 100 J/cm for interstitial lesions and Drug RM-1929: 640mg/m^2", "type": "COMBINATION_PRODUCT" } ], "intervention_types": [ "COMBINATION_PRODUCT" ], "sponsor": "Rakuten Medical, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2015-06", "completion_date": "2019-02-25", "has_results": false, "last_update_posted_date": "2020-02-26", "last_synced_at": "2026-10-01T02:15:36.758Z", "location_count": 7, "location_summary": "San Francisco, California • Denver, Colorado • Chicago, Illinois + 4 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Minneapolis", "state": "Minnesota" }, { "city": "Oklahoma City", "state": "Oklahoma" } ], "official_url": "https://clinicaltrials.gov/study/NCT02422979" }, { "nct_id": "NCT03342196", "title": "Thiotepa Plus Fludarabine+ Melphalan as the Preparative Regime for Alternative Donor Transplantation", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Leukemia" ], "interventions": [ { "name": "Melphalan", "type": "DRUG" }, { "name": "Thiotepa", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Case Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "65 Years", "sex": "ALL", "summary": "1 Year to 65 Years" }, "enrollment_count": 40, "start_date": "2018-03-21", "completion_date": "2024-06-12", "has_results": true, "last_update_posted_date": "2025-12-03", "last_synced_at": "2026-10-01T02:15:36.758Z", "location_count": 1, "location_summary": "Cleveland, Ohio", "locations": [ { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT03342196" }, { "nct_id": "NCT01088048", "title": "Study to Investigate Idelalisib in Combination With Chemotherapeutic Agents, Immunomodulatory Agents and Anti-CD20 Monoclonal Antibody (mAb) in Participants With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Indolent Non-Hodgkin's Lymphoma", "Chronic Lymphocytic Leukemia", "Mantle Cell Lymphoma" ], "interventions": [ { "name": "Idelalisib", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" }, { "name": "Bendamustine", "type": "DRUG" }, { "name": "Ofatumumab", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Everolimus", "type": "DRUG" }, { "name": "Bortezomib", "type": "DRUG" }, { "name": "Chlorambucil", "type": "DRUG" }, { "name": "Lenalidomide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 241, "start_date": "2010-03-25", "completion_date": "2015-04-28", "has_results": true, "last_update_posted_date": "2021-03-18", "last_synced_at": "2026-10-01T02:15:36.758Z", "location_count": 11, "location_summary": "Huntsville, Alabama • Los Angeles, California • Palo Alto, California + 8 more", "locations": [ { "city": "Huntsville", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Bethesda", "state": "Maryland" }, { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT01088048" }, { "nct_id": "NCT00068250", "title": "Combination Chemotherapy, Monoclonal Antibody, and Radiation Therapy in Treating Patients With Primary Central Nervous System Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Brain and Central Nervous System Tumors", "Lymphoma" ], "interventions": [ { "name": "rituximab", "type": "DRUG" }, { "name": "methotrexate", "type": "DRUG" }, { "name": "temozolomide 100 mg/m^2", "type": "DRUG" }, { "name": "temozolomide 150 mg/m^2", "type": "DRUG" }, { "name": "temozolomide 200 mg/m^2", "type": "DRUG" }, { "name": "radiation therapy", "type": "RADIATION" }, { "name": "post-radiation therapy temozolomide", "type": "DRUG" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Radiation Therapy Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 60, "start_date": "2003-07", "completion_date": "2016-12", "has_results": true, "last_update_posted_date": "2018-02-07", "last_synced_at": "2026-10-01T02:15:36.758Z", "location_count": 26, "location_summary": "Jacksonville, Florida • Jacksonville Beach, Florida • Orange Park, Florida + 17 more", "locations": [ { "city": "Jacksonville", "state": "Florida" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Jacksonville Beach", "state": "Florida" }, { "city": "Orange Park", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00068250" } ] }